We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Blood-Screening Market to Reach USD 3.9 Billion in 2024

By LabMedica International staff writers
Posted on 03 Apr 2018
The global blood screening market size was valued at USD 1.6 billion in 2015 and is expected to grow at a CAGR of 10.2% during the forecast period 2016-2024 to reach USD 3.9 billion by 2024, driven by increasing screening of donors and continued technological advancements by the market players. More...
The demand for blood screening tests continues to increase due to growing donations, increasing awareness about transfusion-transmitted diseases, and technological developments in the industry.

These are the latest findings of Grand View Research, Inc. (San Francisco, CA, USA), a market research and consulting company.

Based on technology, nucleic acid amplification test or Nucleic Acid Test (NAT) is expected to be the fastest growing segment during the forecast period, led by its increasing preference over ELISA tests due to the high sensitivity and specificity for viral nucleic acid. Moreover, the contract in 2014 between the Red Cross in Japan and Grifols for NAT for a blood donation camp in Japan is further expected to boost the market for NAT during the forecast period. However, ELISA held the second-largest share of the blood screening market in 2015 due to the continuous development for increasing its specificity, lower cost in comparison to NAT, and rising incidence of infectious diseases in Asia Pacific.

Based on products and services, reagent dominated the blood screening market in 2015 and is expected to maintain its leading position during the forecast period owing to the introduction of new assays for the detection of various diseases. Higher accuracy and specificity in detecting the presence and type of various elements in small sample, cost-effectiveness for customers and high return on investment to vendors is also expected to aid the growth of this market segment. On the other hand, the growth of the instrument segment is expected to be restrained during the forecast period by the high cost and reusable nature of instruments.

Geographically, North America dominated the global blood screening market in 2015 with a revenue share of more than 40% due to the presence of key industry players, rising adoption of blood screening process, stringent FDA regulations for transfusion, and increased patient affordability in the region. However, the Asia Pacific blood-screening market is expected to record the fastest growth during the forecast period, led mainly by Japan, China, India, Singapore, and Australia. Increasing awareness about blood donation and the transmission of diseases during transfusion, rising patient affordability, and growing focus of key industry players on the emerging countries in the region are expected to act as the key growth drivers of the blood screening market in Asia Pacific. However, lower-than-required donation and the high cost of kits and instruments are expected to restrain the growth of the blood screening market in low-income countries during the forecast period.

The market players are adopting the strategies of new products development and partnerships & collaborations for the development and commercialization of products to increase their share. Collaborations for commercialization and development are expected to propel the growth of the blood screening market during the forecast period.

Related Links:
Grand View Research


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.